-+ 0.00%
-+ 0.00%
-+ 0.00%

Mendus, NorthX Biologics Win Grant for Memory Natural Killer Cell-based Therapies Project

MT Newswires·11/10/2026 05:48:21
Listen to the news
05:48 AM EST, 11/10/2026 (MT Newswires) -- Mendus (IMMU.ST) and its manufacturing partner NorthX Biologics secured a 977,300-krona grant from Sweden's innovation agency Vinnova to produce memory natural killer cell-based therapies. The grant, which was awarded under Vinnova's life science infrastructure program, will allow the partners to establish a manufacturing platform for the memory NK cell therapies, according to a Tuesday release. The companies initially collaborated on the production of Mendus' vididencel, a potential blood cancer therapy. The memory NK cells will be produced from healthy donor material using Mendus' DCOne technology.